Workflow
NeuroSense Therapeutics(NRSN)
icon
Search documents
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
Prnewswire· 2025-09-10 18:30
Core Insights - NeuroSense Therapeutics announced positive initial results from the RoAD Phase 2 clinical trial evaluating PrimeC for Alzheimer's disease, demonstrating improvements in brain-cell connectivity and health with a favorable safety profile [1][5][9] Company Overview - NeuroSense Therapeutics is a late-stage clinical biotechnology company focused on developing treatments for severe neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease [11] - The company aims to address significant unmet medical needs in neurodegenerative diseases through combined therapies targeting multiple pathways [11] Clinical Trial Details - The RoAD Phase 2 trial is a randomized, double-blind, placebo-controlled study enrolling mild-to-moderate Alzheimer's disease patients, designed to evaluate the safety, efficacy, and biological activity of PrimeC over 12 months [2][6] - Initial results provide a patient-specific view of how PrimeC may affect disease-relevant human neurons, reinforcing the mechanistic rationale for the treatment [3] Technology and Methodology - NeuroKaire's proprietary technology generates brain cells from patients' blood, reprogramming them into induced pluripotent stem cells (iPSCs) and differentiating them into mature human cortical neurons [4] - Advanced imaging and AI-driven analytics are used to quantify neuronal structure and generate profiles related to neuroplasticity, connectivity, and cell health [4] Drug Candidate Information - PrimeC is NeuroSense's lead drug candidate, an extended-release oral formulation combining two FDA-approved drugs: ciprofloxacin and celecoxib, targeting mechanisms contributing to neuron degeneration and inflammation [8] - The treatment has shown enhanced neuroplasticity, a critical feature for brain health and memory retention, with no treatment-related toxicity observed [9] Future Directions - NeuroSense and NeuroKaire will continue to evaluate PrimeC's cellular effects alongside clinical outcomes from the RoAD trial, with top-line data expected after study completion [6]
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
Prnewswire· 2025-09-04 12:49
Company Overview - NeuroSense Therapeutics Ltd. is a late-clinical stage biotechnology company focused on developing treatments for severe neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease, which represent significant unmet medical needs with limited therapeutic options available [5] Financing Details - NeuroSense has entered into a definitive agreement for a $500,000 private placement of ordinary shares, issuing 333,334 shares at a purchase price of $1.50 per share, which is a 40% premium to the closing price on September 3, 2025 [2][3] - The private placement is expected to close on September 8, 2025, subject to customary conditions, and the proceeds will be used for general corporate purposes and working capital [2] Management Commentary - The CEO of NeuroSense stated that this investment serves as a short-term bridge to advance the company's activities and prepare for the next stage of growth, emphasizing that this is the third financing with private investors at a premium to market [3]
NeuroSense Therapeutics(NRSN) - 2025 Q2 - Quarterly Report
2025-08-01 13:00
| | June 30, | December 31, | | --- | --- | --- | | | 2025 | 2024 | | Assets | | | | Current assets: | | | | Cash and cash equivalent | 666 | 3,378 | | Other receivables | 847 | 989 | | Restricted deposit | 43 | 35 | | Total current assets | 1,556 | 4,402 | | Non-current assets: | | | | Property, plant and equipment, net | 63 | 66 | | Operating right of use assets | 42 | 84 | | Restricted deposit | 23 | 23 | | Total non-current assets | 128 | 173 | | Total assets | 1,684 | 4,575 | | Liabilities and Equity | ...
NeuroSense Provides Business Update and Progress for the First Half of 2025
Prnewswire· 2025-08-01 13:00
Core Insights - NeuroSense Therapeutics is advancing its investigational therapy PrimeC for ALS and preparing for a pivotal Phase 3 trial [2][3] - The first half of 2025 has been transformational for the company, regaining Nasdaq compliance and generating additional long-term data from its Phase 2b study [3][5] Corporate Highlights for H1 2025 - Nasdaq compliance was restored after a $5 million private placement in December 2024, strengthening the balance sheet [5] - New analyses from the Phase 2b PARADIGM study showed PrimeC slowed functional decline by approximately 40%, improved overall survival by 74%, and complication-free survival by 79% [6] - Manufacturing capabilities for PrimeC were successfully scaled to commercial levels, ensuring supply chain readiness [8] Financial Results for H1 2025 - Research and development expenses decreased by 32.9% to $2,503 thousand compared to $3,733 thousand in the same period of 2024 [12] - General and administrative expenses slightly decreased by 4.4% to $2,189 thousand [12] - The net loss for the first half of 2025 was $4,709 thousand, down from $6,261 thousand in the first half of 2024 [12] Future Plans - NeuroSense plans to submit a new request for Notice of Compliance with conditions (NOC/c) in Canada, supported by additional data [11] - A multinational Phase 3 study of PrimeC is expected to commence in the second half of 2025 following positive regulatory feedback from the FDA [11] - Discussions are ongoing with a global pharmaceutical partner to advance the development and commercialization of PrimeC [11]
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
Prnewswire· 2025-07-22 12:42
Core Insights - NeuroSense Therapeutics is a late-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, particularly ALS [12] - The company is set to unveil new insights regarding its investigational therapy PrimeC and its regulatory progress in Canada during a live broadcast event hosted by Aaron Lazar [1][2] Company Overview - NeuroSense Therapeutics is dedicated to discovering and developing therapies for neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's, which represent significant unmet medical needs [12] - The company employs a strategy of developing combined therapies that target multiple pathways associated with these diseases [12] Product Development - PrimeC, NeuroSense's lead drug candidate, is an extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, aimed at addressing key mechanisms of ALS [11] - The Phase 2a clinical trial for PrimeC has met safety and efficacy endpoints, showing potential in reducing functional and respiratory deterioration and demonstrating biological activity through significant changes in ALS-related biomarkers [11] Regulatory Milestones - PrimeC has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency, indicating its potential to address a rare disease with limited treatment options [11] - The upcoming live event will discuss NeuroSense's regulatory path in Canada and the latest developments regarding its binding term sheet with a pharmaceutical partner [2]
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
Benzinga· 2025-05-12 19:08
Core Insights - NeuroSense Therapeutics Ltd. has scaled up the production of its lead drug candidate, PrimeC, to a commercial scale, which is an extended-release oral formulation combining ciprofloxacin and celecoxib for treating amyotrophic lateral sclerosis (ALS) [1][2] - The company has enhanced its supply chain through comprehensive Chemistry, Manufacturing, and Controls (CMC) improvements and has partnered with a global contract development and manufacturing organization (CDMO) for future commercial supply [2][3] - Stability data indicates a shelf life of at least 36 months at room temperature, and the formulation's intellectual property protection extends until 2042 [3] Commercial Potential - Forecasts suggest that PrimeC could achieve peak annual revenues of $100–150 million in Canada [4] - D. Boral Capital has initiated coverage on NeuroSense with a Buy rating and a price target of $14, citing strong mechanistic rationale supported by preclinical and translational research [4] - The ongoing Phase 2b PARADIGM trial is expected to provide further validation, with topline results anticipated in the second half of 2025 [4] Clinical Developments - Recent findings from the Phase 2b PARADIGM clinical trial indicate that PrimeC significantly impacts microRNA modulation, which is crucial for understanding its potential to slow ALS progression [5][6] - The treatment has shown a 33% reduction in disease progression and a 58% improvement in survival rates [6] Expansion and Strategic Partnerships - NeuroSense is exploring expansion into Alzheimer's and Parkinson's diseases, utilizing similar pathophysiologic targets with modified drug combinations, which could broaden its market reach [7] - The company is in advanced discussions with several multi-billion-dollar pharmaceutical companies for a potential strategic partnership to develop and commercialize PrimeC for ALS [8] - The stock price of NeuroSense has increased by 6.34%, reaching $1.11 [8]
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
Prnewswire· 2025-05-07 12:45
Core Insights - NeuroSense Therapeutics has successfully scaled up the production of its ALS therapy, PrimeC, to commercial levels, marking a significant step towards commercialization in a projected $100-150 million Canadian market opportunity [1][4] - The company has enhanced its supply chain with comprehensive Chemistry, Manufacturing, and Controls (CMC) improvements, ensuring a robust infrastructure for commercial launch [2][3] - NeuroSense is collaborating with a global Contract Development and Manufacturing Organization (CDMO) for the production of PrimeC, with validated analytical methods and a confirmed shelf life of at least 36 months at room temperature [3][4] Manufacturing and Regulatory Strategy - The manufacturing milestone is seen as a critical advancement in the company's commercialization roadmap, positioning PrimeC for rapid entry into the Canadian market upon regulatory approval [4] - NeuroSense is pursuing early market entry through the Notice of Compliance with Conditions (NOC/c) pathway with Health Canada, aimed at expediting access to therapies for serious conditions [4] - The company’s patent protection for PrimeC extends through 2042, reinforcing its market position and long-term growth strategy [4] Market Potential and Company Overview - The potential peak annual revenue for PrimeC in Canada is estimated between $100 million and $150 million, addressing significant unmet medical needs in ALS treatment [4] - NeuroSense focuses on developing treatments for severe neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's, which represent significant unmet medical needs [5]
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
Prnewswire· 2025-04-24 13:09
Core Insights - NeuroSense Therapeutics is progressing towards a Phase 3 clinical trial for PrimeC in ALS, with a positive regulatory pathway and ongoing partnership discussions with a global pharmaceutical company [1][5][3] Strategic Partnership Update - The company entered a binding term sheet with a leading global pharmaceutical company in December 2024, although finalizing the agreement has taken longer than anticipated due to its complexity [3][4] - Ongoing communications with the potential partner are constructive, and the company remains optimistic about the collaboration's potential impact [4] Regulatory and Commercial Pathway - Following positive feedback from the FDA, the Phase 3 clinical trial is set to begin in the second half of 2025, with sites primarily in the U.S. and Europe [5] - In Canada, discussions with Health Canada are progressing towards a potential Notice of Compliance with Conditions (NOC/c) pathway, which would allow earlier access to PrimeC for patients [6][7] - The potential peak annual revenue in Canada is estimated at $100–150 million, with a focus on addressing the unmet needs of the ALS community [7] Clinical Program Progress - The Phase 2b PARADIGM study showed a statistically significant 33% slowing of disease progression and a 58% improvement in survival rates compared to placebo [10] - PrimeC has demonstrated a favorable safety and tolerability profile, with high participant retention rates [11] Scientific Validation and Mechanism Insights - Recent biomarker findings presented at a neurology conference validate PrimeC's mechanism of action and its ability to modulate key disease-related biomarkers [12][13] Financial Outlook - The potential strategic partnership is expected to enhance the company's financial position through upfront capital and funding for the Phase 3 program [14] - The company has no immediate plans for additional capital raising but will evaluate opportunities as they arise [15] Looking Forward - The upcoming months are critical for NeuroSense as it prepares for the Phase 3 trial, advances regulatory discussions in Canada, and works towards finalizing the strategic partnership [16]
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
Prnewswire· 2025-04-09 12:30
Core Insights - NeuroSense Therapeutics announced promising findings from its Phase 2b PARADIGM clinical trial, highlighting the significant impact of its investigational therapy PrimeC on microRNA modulation in ALS patients [1][2] Group 1: Clinical Trial Findings - The PARADIGM trial demonstrated a consistent downregulation of 161 mature miRNAs in ALS patients treated with PrimeC, with no significant changes in the placebo group, indicating PrimeC's targeted biological activity [3] - PrimeC treatment resulted in the downregulation of ALS-related miRNAs, specifically miR-199 and miR-181, which are associated with disease progression and survival, correlating with reported improvements in clinical function [4][7] Group 2: Research Collaboration and Presentation - The research was conducted in collaboration with Prof. Noam Shomron from Tel Aviv University, a leader in microRNA research, and presented by Dr. Jeffrey Rosenfeld at the 77th Annual American Academy of Neurology Meeting [5][6] Group 3: Mechanistic Insights and Future Development - NeuroSense aims to deepen mechanistic insights and identify miRNA-based biomarkers for treatment response, with the Phase 2b data providing a foundation for further investigations into PrimeC's impact on miRNA maturation and relevance in other neurodegenerative diseases [6] Group 4: About ALS and PrimeC - ALS is an incurable neurodegenerative disease with a significant annual burden of $1 billion in the U.S., affecting over 5,000 people annually, and is expected to grow by 24% by 2040 [9] - PrimeC is a novel extended-release oral formulation combining two FDA-approved drugs, designed to target multiple mechanisms of ALS, and has shown efficacy in reducing functional and respiratory deterioration [10]
NeuroSense Therapeutics(NRSN) - 2024 Q4 - Annual Report
2025-04-07 21:25
[Executive Summary & Business Highlights](index=1&type=section&id=Executive%20Summary%20%26%20Business%20Highlights) NeuroSense Therapeutics achieved significant clinical and strategic milestones in 2024, including successful Phase 2b ALS study results, FDA alignment for Phase 3, and extended patent protection [2024 Business Highlights](index=1&type=section&id=Business%20highlights%20from%202024%20and%20to%20date) NeuroSense Therapeutics achieved significant clinical progress in 2024, successfully completing its Phase 2b study for PrimeC in ALS, demonstrating slowed disease progression and improved survival rates. The company also aligned its Phase 3 study design with the FDA for planned initiation in 2025, is pursuing partnership discussions, and plans for early commercialization in Canada, supported by an extended patent until 2042 PrimeC Phase 2b Study Results | Metric | Result | | :--- | :--- | | Slowed disease progression (ALSFRS-R) | ~33% after 18 months (p=0.007) | | Overall improvement in survival rates | 58% (reduced mortality, hospitalization, respiratory support) | | Slowed functional decline | Especially speaking and swallowing functions | | Safety and tolerability | Favorable profile (achieved primary endpoint) | - **Phase 3 study design** for PrimeC in ALS aligned with FDA; planned initiation in **2025**[3](index=3&type=chunk) - Plans to file for early commercialization for PrimeC in Canada, with an estimated potential market opportunity of **$100 million-$150 million** in peak annual revenues[3](index=3&type=chunk) - Key patent granted by U.S. Patent and Trademark Office (USPTO), extending patent protection for PrimeC until **2042**[4](index=4&type=chunk) [CEO Statement](index=2&type=section&id=CEO%20Statement) NeuroSense CEO, Alon Ben-Noon, highlighted 2024 as a year of significant clinical progress, emphasizing the transformative results of the PrimeC Phase 2b study in ALS and its disease-modifying potential, which strongly supports advancing PrimeC to a Phase 3 study with positive FDA feedback - NeuroSense CEO, Alon Ben-Noon, stated: "**2024** was a year of **significant clinical progress** for NeuroSense"[4](index=4&type=chunk) - The results conclude with PrimeC's **disease-modifying potential** and strongly support advancing PrimeC towards a **Phase 3 study**[4](index=4&type=chunk) [Financial Results](index=2&type=section&id=Financial%20Results) NeuroSense Therapeutics reported a decrease in both research and development and general and administrative expenses for 2024, while increasing its cash position and significantly improving its equity from a deficit to a positive balance [Summary of Key Financials](index=2&type=section&id=Summary%20of%20Key%20Financials) NeuroSense Therapeutics reported a decrease in both research and development expenses and general and administrative expenses for the year ended December 31, 2024, compared to 2023, while increasing its cash position Research and Development Expenses (in thousands) | Year | Amount | Change (YoY) | | :--- | :--- | :--- | | 2024 | $5,700 | -$1,600 (-21.9%) | | 2023 | $7,300 | | General and Administrative Expenses (in thousands) | Year | Amount | Change (YoY) | | :--- | :--- | :--- | | 2024 | $4,200 | -$600 (-12.5%) | | 2023 | $4,800 | | - Cash as of December 31, 2024: approximately **$3.4 million**[7](index=7&type=chunk) [Consolidated Statements of Financial Position](index=3&type=section&id=Consolidated%20Statements%20of%20Financial%20Position) The Consolidated Statements of Financial Position show NeuroSense's financial health as of December 31, 2024, with total assets increasing to $4.575 million from $3.185 million in 2023, and a significant shift from a total shareholders' deficit of $(1.759) million in 2023 to a positive equity of $2.583 million in 2024 Consolidated Statements of Financial Position (U.S. dollars in thousands) | Item | As of December 31, 2024 | As of December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Current assets: | | | | Cash and cash equivalent | $3,378 | $2,640 | | Other receivables | 989 | 236 | | Restricted deposits | 35 | 40 | | Total current assets | 4,402 | 2,916 | | Non-current assets: | | | | Property and equipment, net | 66 | 85 | | Right of use assets | 84 | 162 | | Restricted deposit | 23 | 22 | | Total non-current assets | 173 | 269 | | **Total assets** | **$4,575** | **$3,185** | | **Liabilities shareholders' and equity** | | | | Current liabilities: | | | | Trade payables | $1,160 | $1,459 | | Other current liabilities | 832 | 2,000 | | Total current liabilities | 1,992 | 3,459 | | Non-current liabilities: | | | | Lease liability less current maturity | - | 73 | | Liability in respect of warrants | - | 1,412 | | Total non-current liabilities | - | 1,485 | | **Total liabilities** | **1,992** | **4,944** | | **Shareholders' equity:** | | | | Share Premium and Capital Reserve | 39,243 | 24,362 | | Accumulated deficit | (36,660) | (26,121) | | **Total shareholders' equity (deficit)** | **2,583** | **(1,759)** | | **Total liabilities and shareholders' equity** | **$4,575** | **$3,185** | [Consolidated Statements of Income and Comprehensive Loss](index=4&type=section&id=Consolidated%20Statements%20of%20Income%20and%20Comprehensive%20Loss) The Consolidated Statements of Income and Comprehensive Loss for 2024 show a net loss of $(10.210) million, a slight increase from $(10.107) million in 2023, despite a reduction in both research and development expenses and general and administrative expenses, primarily due to a negative shift in financing income (expenses), net Consolidated Statements of Income and Comprehensive Loss (U.S. dollars in thousands, except share and per share data) | Item | For the year ended December 31, 2024 | For the year ended December 31, 2023 | For the year ended December 31, 2022 | | :--- | :--- | :--- | :--- | | Research and development expenses | $(5,698) | $(7,274) | $(5,587) | | General and administrative expenses | $(4,204) | $(4,775) | $(4,967) | | **Operating loss** | **$(9,902)** | **$(12,049)** | **$(10,554)** | | Financing income (expenses), net | $(308) | $1,942 | $62 | | **Net loss and comprehensive loss** | **$(10,210)** | **$(10,107)** | **$(10,492)** | | Basic and diluted net loss per share | $(0.54) | $(0.74) | $(0.91) | [Consolidated Statements of Changes in Equity (Deficit)](index=5&type=section&id=Consolidated%20Statements%20of%20Changes%20in%20Equity%20(deficit)) The Consolidated Statements of Changes in Equity (Deficit) reflect a significant improvement in NeuroSense's equity position, moving from a deficit of $(1,759) thousand at the end of 2023 to a positive equity of $2,583 thousand by December 31, 2024, driven by issuance of shares and pre-funded warrants, reclassification of warrants, and bonus accruals, despite a net loss Consolidated Statements of Changes in Equity (deficit) (U.S. dollars in thousands, except share and per share data) | Item | Ordinary Shares Number | Ordinary Shares Amount | Share Premium and Capital Reserve | Accumulated Deficit | Total Equity (Deficit) | | :--- | :--- | :--- | :--- | :--- | :--- | | Balance as of January 1, 2022 | 10,943,534 | $ - | $ 16,356 | $ (5,522) | $ 10,834 | | Repurchase of options | - | - | (96) | - | (96) | | Exercise of warrants and vested RSUs | 838,429 | - | 3,870 | - | 3,870 | | Share based payment compensation | - | - | 1,728 | - | 1,728 | | Net loss and comprehensive loss | - | - | - | (10,492) | (10,492) | | **Balance as of December 31, 2022** | **11,781,963** | **$ -** | **$ 21,858** | **$ (16,014)** | **$ 5,844** | | Issuance of shares and pre-funded warrants, net | 1,333,600 | - | 806 | - | 806 | | Exercise of pre-funded warrants, options and vested RSUs | 2,263,479 | - | - | - | - | | Share based payment compensation | - | - | 1,698 | - | 1,698 | | Net loss and comprehensive loss | - | - | - | (10,107) | (10,107) | | **Balance as of December 31, 2023** | **15,379,042** | **$ -** | **$ 24,362** | **$ (26,121)** | **$ (1,759)** | | Issuance of shares and pre-funded warrants, net | 5,981,238 | - | 10,806 | - | 10,806 | | Exercise of pre-funded warrants, options and vested RSUs | 1,573,000 | - | (*) | - | (*) | | Issuance of shares due to SEPA agreement | 224,697 | - | 281 | - | 281 | | Reclassification of warrants into equity (see Note 8) | - | - | 1,695 | (329) | 1,366 | | Bonus accrual reclassification to equity (see Note 14) | - | - | 1,434 | - | 1,434 | | Share-based compensation | 70,964 | - | 665 | - | 665 | | Net loss and comprehensive loss | - | - | - | (10,210) | (10,210) | | **Balance as of December 31, 2024** | **23,228,941** | **$ -** | **$ 39,243** | **$ (36,660)** | **$ 2,583** | [Company and Product Information](index=6&type=section&id=Company%20and%20Product%20Information) This section provides essential information about Amyotrophic Lateral Sclerosis (ALS), NeuroSense's lead drug candidate PrimeC, and the company's strategic focus on neurodegenerative disease treatments [About ALS](index=6&type=section&id=About%20ALS) Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease leading to complete paralysis and death within 2-5 years. It affects over 5,000 people annually in the U.S., with a $1 billion annual disease burden, and is projected to increase by 24% by 2040 in the U.S. and EU - ALS is an incurable neurodegenerative disease that causes complete paralysis and death within **2-5 years** from diagnosis[18](index=18&type=chunk) - More than **5,000 people** are diagnosed with ALS in the U.S. alone each year, with an annual disease burden of **$1 billion**[18](index=18&type=chunk) - The number of people living with ALS is expected to grow by **24%** by **2040** in the U.S. and EU[18](index=18&type=chunk) [About PrimeC](index=6&type=section&id=About%20PrimeC) PrimeC is NeuroSense's lead drug candidate, an extended-release oral formulation combining ciprofloxacin and celecoxib. It targets multiple ALS mechanisms, has met safety and efficacy endpoints in a Phase 2a trial, and holds Orphan Drug Designation from the FDA and EMA - PrimeC is NeuroSense's lead drug candidate, a novel extended-release oral formulation composed of a unique **fixed-dose combination** of two FDA-approved drugs: ciprofloxacin and celecoxib[19](index=19&type=chunk) - PrimeC is designed to **synergistically target multiple mechanisms** of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation, and impaired RNA regulation[19](index=19&type=chunk) - PrimeC was granted **Orphan Drug Designation** by the U.S. Food and Drug Administration and the European Medicines Agency[19](index=19&type=chunk) [About NeuroSense](index=6&type=section&id=About%20NeuroSense) NeuroSense Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing combined therapies for severe neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, addressing significant unmet medical needs through a multi-pathway targeting strategy - NeuroSense Therapeutics, Ltd. is a **clinical-stage biotechnology company** focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases[20](index=20&type=chunk) - NeuroSense's strategy is to develop **combined therapies targeting multiple pathways** associated with these diseases[20](index=20&type=chunk) [Additional Information](index=6&type=section&id=Additional%20Information) This section outlines forward-looking statements, emphasizing inherent risks and uncertainties, and provides contact information for NeuroSense Therapeutics [Forward-Looking Statements](index=6&type=section&id=Forward-Looking%20Statements) This section contains forward-looking statements subject to substantial risks and uncertainties, including those related to partnership discussions, study initiation timing, regulatory filings, market potential, and financial resources. Investors are cautioned not to rely on these statements, and NeuroSense undertakes no duty to update them except as required by law - This press release contains "forward-looking statements" that are subject to **substantial risks and uncertainties**[22](index=22&type=chunk) - Risks include the risk that **partnership discussions** will not lead to a definitive agreement, delays in the planned **Phase 3 study**, lower than anticipated **market opportunity**, delayed or unobtained **regulatory approvals**, unexpected **R&D costs**, **insufficient capital**, and other risks detailed in SEC filings[22](index=22&type=chunk) - NeuroSense undertakes **no duty to update** such information except as required under applicable law[22](index=22&type=chunk) [Contact Information](index=6&type=section&id=For%20further%20information) Contact details for NeuroSense Therapeutics are provided for further information - Email: info@neurosense-tx.com[23](index=23&type=chunk) - Tel: +972 (0)9 799 6183[23](index=23&type=chunk)